List view / Grid view
6 February 2015 | By The Cochrane Library
The Cochrane Library recently published a review of chondroitin sulfate that confirms the efficacy and safety of this drug in the treatment of osteoarthritis...
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
5 February 2015 | By BIOTRONIK
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that patient enrollment for the BIOFLOW-IV study has been completed...
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
4 February 2015 | By Genmab
Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech...
4 February 2015 | By GlobalData
The French pharmaceutical market is forecast to grow at a tepid Compound Annual Growth Rate (CAGR) of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, restricted by an increasing focus on generic drugs, according to research and consulting firm GlobalData...
3 February 2015 | By Lilly Diabetes
Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships...
3 February 2015 | By AYOXXA Biosystems / SERI
AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools...
3 February 2015 | By Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…
3 February 2015 | By Coulter Partners
Coulter Partners, the Global Life Sciences search specialist, is pleased to announce the appointment of Eskil Westh as Executive Vice President...
3 February 2015 | By Roche
Roche today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. at a price of $50.00 per share...
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
2 February 2015 | By CPhI Worldwide
Experts from CPhI Worldwide have shared their pharma predictions for 2015, suggesting that Continuous Manufacturing and QbD will expand, with FDA becoming ‘industry tutor’. However, pharma concerns about supply chain persist...
